中文摘要：

目的观察玻璃体注射雷珠单抗治疗老年黄斑变性黄斑水肿（AMD-ME）与视网膜静脉阻塞性黄斑水肿（RVO-ME）的短期临床效果。设计回顾性病例系列。研究对象2015年10月至2016年7月确诊为AMD-ME及RVO-ME的患者共30例（30眼）,各15例（15眼）。方法患眼接受玻璃体注射雷珠单抗（0.5 mg/0.05 ml）治疗,采用1＋PRN的注射方法,比较治疗前和治疗后1天、1个月最佳矫正视力（BCVA）、眼压（IOP）、黄斑中心凹视网膜厚度（CMT）、注射后消除的水肿高度,评价每次随访时检查结果。主要指标BCVA、CMT、消除的水肿高度、IOP。结果 AMD-ME组及RVO-ME组注射雷珠单抗后1天、1个月的BCVA均较术前提高（P=0.000、0.000）。AMD-ME组及RVO-ME组每次治疗前和治疗后1个月CMT厚度均降低（P=0.000、0.000）。治疗过程中患者眼压与治疗前比较并无明显变化（P=0.096、0.066、0.213、0.088、0.240、0.337）。结论玻璃体注射雷珠单抗治疗AMD-ME及RVO-ME在短期内均可减轻黄斑水肿和改善视力,两者治疗效果无明显差异。

英文摘要：

Objective To investigate the short-term clinical effects of the ranibizumab intravitreal injection on age related macular degeneration macular edema（AMD-ME） and retinal vein occlusion macular edema（RVO-ME）. Design Retrospective case series. Participants 30 patients（30 eyes） with 15 AMD-ME and 15 RVO-ME. Methods All patients received ranibizumab 0.05 ml intravitreal injection, using 1＋PRN injection algarism. The follow-up examinations were at 1 day, 1 month after the treatment. The best corrected visual acuity（BCVA） and central macular thickness（CMT） were observed and compared between AMD-ME patients and RVO-ME patients before and after injection. Main Outcome Measures BCVA, CMT, IOP. Results The BCVA of both AMD-ME group and RVO-ME group improved significantly at 1 day and 1 month after the ranibizumab intravitreal injection（ P=0.000, 0.000）. The CMT reduced significantly for both group as well（P=0.000, 0.000）. The IOP did not change significantly during the treatment（P=0.096, 0.066,0.213, 0.088, 0.240, 0.337 for different time points）. Conclusion Ranibizumab intravitreal injection can reduce macular edema and improve the visual activity in patients with AMD-ME or RVO-ME. The treatment effect was similar for AMD-ME and RVO-ME.